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Abstract 
Little is known about why patients with cancer do or do not donate their tissue for 
research.  A review of the literature on motivations to participate in clinical research and 
to donate tissues/organs for therapeutic use may provide some insights relevant to 
tumour banking research.  While more research is necessary, a better understanding of 
the reasons that motivate patients to give or refuse consent to tumour banking may 
ultimately improve consent practices, public trust and donation rates.  
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 Tumour banks are generally regarded as an essential resource for research into the 
biology of cancer [1-3]. Collections of tissue, usually removed in the course of diagnostic 
or therapeutic procedures, enable studies to be carried out linking abnormalities in the 
tissue to disease aetiology, prognosis and treatment responsiveness. Moreover, storage 
over time enables laboratory findings to be correlated with disease progression and 
patient response to treatment, as well as enabling as-yet undiscovered techniques to be 
applied in the future to previously collected samples.  
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 When tumour samples are collected from patients in the course of diagnosis or 
therapy, patients are asked whether they would like to donate their tissue sample to 
research.  Consent to this donation means that their tissue sample will be placed in a 
tissue, or tumour bank.  There are many kinds of tissue banks organized according to a 
number of demographic factors such as age, geographic location, cultural groups or 
disease groups.   
 For many years, the secondary use of diagnostic and therapeutic tissues in research 
did not cause much ethical concern. There was little specific regulation and consent for 
tumour banking research, if obtained at all, was obtained in a “blanket” fashion, asking 
patients to authorise the use of their tissues for any kind of research. This approach was 
widely supported by researchers and was not illegal [3]. The ethical requirement that 
consent to research be “specific” was interpreted broadly and waiver criteria for 
consent, such as “inconvenience” and “public interest”, were applied liberally [3,4].  
Recently, however, controversy has arisen about the practices of collecting, storing and 
using human tissue for research purposes. This controversy is due, in part, to a series of 
media exposures of “scandalous”, non-consensual retention of organs from post-
mortem examinations in several countries including the United Kingdom and Australia 
[5,6].  
 Insofar as donation is offered, participation rates are generally high and few patients 
refuse to have their tissue stored.  Consent to tumour banking research is still an ethical 
concern however particularly in regards to the manner in which consent should be 
obtained, the meaning and implications of their consent (specifically whether recurrent 
project-specific consent is needed) and whether, and to whom, tissue-derived data can 
be disclosed [2,3,7-9].  Other ethical issues relate to whether tissue can be owned and 
sold, since it is becoming clear that commercial uses of tissue are unacceptable to some 
tissue donors [3,10-12] and whether tissue is “sacred” and, therefore, different to other 
kinds of health information, such as medical records and genetic databases[13]. Finally, 
there is discussion about whether the laboratory-based epidemiological techniques 
typically used in “tissue banking research” are well founded scientifically and whether, 
therefore, such research – which poses a small risk to participants – is ethical [14]. 
 Given these ongoing and somewhat intractable controversies, we believe that it is 
important to understand not only the scientific, ethical and legal issues raised by tumour 
banking, but also the reasons why people may choose to donate or to refuse such 
donation. If one is to truly respect a donor’s autonomy, for example, then one needs to 
use tissue in a manner that is consistent with what is important to them, their 
intentions, imagined goals, interests, and choice of action. While some empirical 
research into the values of donors has been carried out [15-23], there has been very 
little research into what motivates patients with cancer to donate their tissue.  We offer 
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critical evaluation of the published literature and provide some conclusions based on 
that literature that may provide a new understanding of a rapidly moving field. 
 The meaning, nature and origin of human motivation is a complex philosophical, 
psychological and sociological issue, with motivations being defined in terms of, among 
other things, discourses, internal states and needs [24-27].  For the purposes of this 
series of speculations about tumour tissue donation, we have chosen to define 
“motivation’ simply as the socially-shaped reason or reasons one has (or cites) for acting 
or behaving in a particular way[28].  Using this definition, we have identified a number 
of reasons that have, or may, be cited for participating, or not participating in tumour 
banking research, clinical research and live therapeutic (organ/tissue/blood) donation. 
 In seeking to understand the motivations to donate tumour samples it is worthwhile 
considering the ways in which tumour banking research is like, and unlike, other forms 
of voluntarism in medicine; namely: the decisions to participate in clinical research and 
the decision to donate “live” therapeutic tissue (organs/ tissue/ blood).  If tumour 
banking is simply a variant of these other practices, then we are likely to already have a 
good understanding of the issues at stake, and we may already be able to derive 
processes/practices for increasing rates of donation [29].  If, on the other hand, tumour 
banking does raise unique issues, then it is important to establish exactly what these 
may be, so that emerging consent procedures, and regulation more generally, can 
accommodate them. Understanding motivations to donate tissue may have profound 
implications for tumour banking research as it is conceivable that the current trend of 
increasingly stringent privacy and consent requirements may not be consistent with the 
motivations and beliefs of patients/donors and so may be unnecessary or even counter-
productive. 
 
Possible motivations for donation of tumour samples 
 
Altruism 
 Decisions to participate in acts that are of no immediate benefit to the person such 
as participating in any kind of research or therapeutic donation are often cited as 
examples of altruism [30-33]. Altruism refers to voluntarily performed behaviour that 
intentionally benefits another person without expectation or reward.  Several writers 
suggest that the motivational forces behind altruistic behaviour include internalized 
feelings of personal obligation.  In his analysis of bone marrow donation, Schwartz [34] 
found that such altruistic behaviour was a function of the person’s feelings of moral 
obligation to carry out this action.   
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 Altruism in the case of tissue donation may be attributed to notions of one’s identity 
as an altruist [35] and may be directed towards specific future patients or family 
members [36] or more generally towards society.  In his study of reasons why new 
mothers decided to provide placenta, cord tissue and maternal blood to a DNA bank, 
Barr reports that many mothers donated because they or someone close to them had 
benefited from research done previously [37].  In this context, the request for tissue for 
the purpose of bio-banking afforded them an opportunity to contribute to research that 
might one day benefit a family member or others.  In the case of cancer, donating 
tumour samples to a research bank may be an opportunity to engage with the “good” 
by contributing to cancer research, while receiving some consolation to the solitude and 
deep pain that is engendered by this illness. In this sense, tumour banking research has 
much in common with each of the comparators, since altruism is a key motivating factor 
for those participating in any kind of research [32,36] as well as in therapeutic donation 
[38,39].  
 The altruistic forces behind tumour banking may, however, differ from those in 
some kinds of clinical research and therapeutic donation because the physical risks to 
tumour tissue donors are relatively small when compared to those who donate solid 
organs, and those participating in clinical research, and therefore demand less of the 
donor.  The decision to donate tissue in tumour banking may require little of the donor 
in terms of time commitments or harm above and beyond the removal of the tumour 
for diagnostic or therapeutic purposes. On the other hand, the potential benefits to 
society are relatively unclear given the open-ended nature of tumour banking research, 
which may make it less clear to donors why they should participate.  
 Another factor that may differentiate altruism in the tumour banking setting from 
altruism in other settings: the fact that what is being given up is diseased tissue (a 
tumour), rather than one’s time, personal comfort and safety, or parts of one’s 
“healthy” body.  While the objects of live organ and tissue donation for transplantation, 
such as kidneys, livers and blood, are seen as objects of value in society that can give life 
and save life, to the cancer patient, the tumour could be seen as nothing more than a 
waste product: a pollutant, or worse, an immanent threat to one’s health.  Symbolism 
and ideology surrounding tumours also invoke great anxieties and fears within the 
person [40]. This negative symbolism may in turn change the nature of altruism since 
people may not see themselves as giving up anything of value and may not understand 
the potential value of the tumour to researchers.  In the case of tumour banking, while 
the donation may have little meaning for the donor, the recipient (the researcher) may 
gain considerable epistemic value from that tissue.   
 
 5 
Egoistic Motives and Personal Benefit 
 A number of writers have questioned conceptions of altruistic donation, suggesting 
that patients may donate tissue for “selfish” reasons, including the desire to affirm ones 
identity or the expectation that they will benefit personally from research.  Boe and 
Ponder [41] found that blood donors provided blood with the expectation of something 
in return.  Similarly, Edwards et al [42] found that in the clinical trial setting, self 
interest, rather than altruism, may be a patient’s main motive for participation. 
 Clinical researchers have long recognised that the patient’s decision to participate in 
research can be motivated by, or reflect, egoistic motives.  It is recognised that, rightly 
or wrongly, people may consent to participate in clinical trials because they expect to 
benefit directly from the research (i.e. the “therapeutic misconception.”) The 
therapeutic misconception involves a belief that the treatment will be individualised to 
the subject, overestimations of therapeutic benefits from research participation, failure 
to perceive that risks from participation in research may be higher than that of 
therapeutic clinical care, and general misunderstandings of the research design 
[30,32,43,44].  While the therapeutic misconception is much less likely to be a factor in 
tumour banking research than clinical research, it is still possible that donors may 
perceive that research on their tissue may lead to a cure for their own cancer, or may 
confuse the collection of their tissue sample for research with further testing for their 
own diagnosis and treatment.   
 Immense anxiety, uncertainty, and ontological insecurity [40, 45] characterise the 
experience of cancer and this anxiety may itself be a major motivating force - rallying, 
propelling and stimulating individuals to act [30].  Patients with cancer may also be 
motivated by their disease to donate tumour samples because this provides them with 
at least a symbolic means for “taking control” of a force that threatens to overwhelm 
every aspect of their life. (While this desire for agency may be particularly strong in the 
case of cancer, this motivation to donate is not unique to tumour banking research and 
may apply to any seriously ill person being asked to participate in research.)   
 
Social Exchange, the Formation of Social Bonds and the “Gift Relationship” 
 In recent years, sociologists have suggested that donation of time, services, organs 
and tissue may be best understood as a social exchange, or as the giving or receiving of 
“gifts”[46,47].  This is often called the “gift relationship”.  The basic idea is that gifts of 
blood and tissue may reinforce existing social ties and enrich or create intimate 
relationships between donors and others, including the patient’s health care providers.  
Patients therefore, may be motivated to provide tissue both by the desire to please 
their treating physician (and her/his research colleagues), and by the desire to respond 
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to kind acts of health care providers with kindness.  In the case of tissue donation, the 
gift of healthcare, of diagnosis and treatment elicits another gift of kindness- tissue 
donation  [30].  In the ‘shared common universe’ of clinical care, tissue donation may 
therefore strengthen social solidarity with those who provide the donor with treatment 
and care [48].  In his analysis of motivation, Giddens identifies the desire of social agents 
to realize trust in their transactions with others as a central motivation [49].   Similarly, 
Milbank [50] argues that the gift exchange helps form and cement ‘primary social 
bonds’ that ‘connect and unite’ patients with their caregivers.  These constructions of 
tissue donation as a form of social exchange or therapeutic relationship appear to be 
supported by empirical research as studies by Pilliavin and Callero [51] and Zaller et al 
[52] both found that blood donors often are “motivated” to donate by personal 
requests and social pressure.  
 
Possible motivations to refuse donation of tumour samples 
While a number of clinical, social and ontological forces may motivate patients to 
donate their tissue for research, different influences may lead them to refuse consent. 
Potential harms 
 It has been suggested that the main concern for those deciding whether to donate 
their tissue for research is whether their confidentiality will be breached and their 
personal information (especially genetic information) misused by “non-scientific” 
entities including insurance companies and employers [3,15,16]. This issue is, however, 
clearly not one limited to tumour banking, as any research that gives third parties access 
to personal information raises similar privacy concerns[3].  Likewise, while it has been 
suggested that concerns about the sale or use of donated, or personal information, 
commercial organisations may be an issue in tissue banking research, this concern also 
arises in relation to clinical trials (which are often industry-sponsored) and in the 
context of therapeutic “live” tissue donation, such as in blood donation [3,15,16]. 
 
Status of human tissue 
In recent years, it has been recognised that the body, and certain tissues in particular, 
may have specific cultural value and that these values may determine the likelihood of 
donation.  In particular, it has been proposed that people from certain religious or 
ethnic groups may be unwilling to donate tissue because the tissue is in some way 
sacred or precious to them [13,53,54].  Whether the cultural value attached to tissue 
changes as tissue becomes pathological (cancerous) is an important issue here as this 
distinguishes the cultural context of tumour banking from other forms of research and 
from donation for transplantation.   If tumour tissue is regarded as waste material or a 
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threat to security or one’s well being, and not afforded the status attributed to healthy 
tissues and organs then many of the concerns relating to the cultural value of tissue may 
disappear.  The few empirical studies that have examined this question suggest that the 
nature of the tissue sample, or the way the sample is described discursively may play a 
significant part in decisions to donate. The North Cumbria Community Genetics project, 
for example, which collected placental and umbilical cord tissue, found that mothers 
who donated, reported that their decision was relatively unproblematic as it involved 
the giving away of ”waste material”, material that was normally “thrown away” [37].  
 
Lack of a pre-existing social imperative 
 The extent to which clinicians and researchers can influence people to donate tissue 
or organs may depend, in part, on whether they are familiar with, and supportive of, the 
entity to which their tissue will be donated.  This issue becomes clear when one 
compares tumour donation to therapeutic organ and blood donation. The majority of 
the public are aware of therapeutic donation and often have considered whether or not 
they would like to participate in donation. In contrast, tumour banking is a relatively 
new and abstract phenomenon that is still entering the public consciousness, and most 
potential tumour donors will not have previously reflected upon whether or not they 
wish to participate in such research.  Thus, when confronted with a request to donate 
tumour tissue, the patient’s attention may be focussed on what is likely to be an 
unfamiliar object in an otherwise typical (clinical) surrounding.  In contrast to 
therapeutic tissue/organ donation, patients approached to donate to tumour banks lack 
the past experiences and ‘stocks of interpretive’ knowledge that are relevant for 
decisions to act on a request that they donate tumour tissue [55].  In these situations, 
patients must discover what tumour banking is, why it is beneficial and how they may 
contribute. Decisions to donate tissue are therefore likely to be influenced strongly by 
the information that clinicians and researchers provide about the risks and benefits of 
tumour banking [55]. 
  
Perception of loss of control 
 One key distinction between tissue banking research and other kinds of research 
and other kinds of therapeutic donation is that tissue is stored indefinitely [56,57].  
While this provides the very basis of its ongoing benefit, it also raises the possibility of 
ongoing harms and of unanticipated future harms. In this sense, tumour banking differs 
from clinical research, where the intervention usually takes place at one point in time 
and where subjects may have a direct and ongoing relationship with the researchers and 
are able to withdraw from the research at any time according to their preference and/or 
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their changing perceptions of benefit.  In tissue banking research, the subject of interest 
(the patient’s tissue) may be sent offshore and/or provided to third parties, meaning 
that neither the patient nor the researcher has control over the scientific or commercial 
use of that tissue.  While there is limited evidence that this is a real concern for patients, 
the perception of loss of control may influence the decision to donate, and certainly 
drives ever-increasing demand for ongoing contact with donors and for project specific 
consent.  This may, in time, be shown to be a genuine issue for patients and their 
families.  
 
Summary 
 It is clear that the influences of decisions to donate tissues to tumour banks both 
overlap with, and differ from, those that influence decisions to participate in clinical 
research and donate live therapeutic tissues. Like clinical research and live therapeutic 
donation, the decision to donate tumour tissue may rest on a combination of altruism, 
egoism and social exchange.  But decisions to donate to tumour banks may differ in 
three main ways: 1) the negative symbolic and linguistic associations of cancer may 
determine both the degree to which donation is altruistic and perceptions of the 
integrity or “sacredness” of tissue; 2) potential donors are likely to be unaware of 
tumour banking, and so may be less cognisant of its risks and benefits and more 
susceptible to influence, and 3) as researchers may have ongoing access to banked 
tissues, both the real and perceived unspecified risks may influence the decisions of 
donors.  
 
Practical implications 
 There are four major practical implications that result from an awareness of the 
reasons why people may decide to donate to a tumour bank.  The first is the need to 
explicitly acknowledge the central importance of the relationships between patients and 
their care givers/ researchers in decisions to donate tissue.  The second is the impact 
that public education about tumour banking research may have on donation rates.  The 
third the continuing uncertainty regarding the optimal means for obtaining consent 
where future research projects may be unanticipated: open-ended consent or project-
specific consent.  And the fourth is the need to explicitly acknowledge how a cancer 
diagnosis may change the way that potential donors think about donation of the tumour 
tissue.  (As the first three issues are extensively addressed in the literature, they will not 
be discussed further here.) 
 It is important that the negative symbolism of the tumour be acknowledged during 
the consent process for two reasons. First, it is important that patients’ desires to be rid 
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of the tumour be validated while at the same time ensuring that patients are not 
consenting to research simply out of an impulsive, anxious desire to be “rid” of the 
tumour. Second, it is important to ensure that patients understand that while their 
tissue may have no value to them, and may even be repulsive and terrifying, it has 
potentially great value to medical research. This type of dialogue seems important 
because it clearly asserts the value of tumour banking research, and because it 
recognises the value of the patient’s “gift”.  If we believe that self-realisation as a result 
of donation is an outcome that is valued in the clinical and research setting, then 
tumour donors should be encouraged to recognize the epistemological value of their 
donation for research, even though the tumour itself may have no value to them.   
 While review of the motivations that drive participation in clinical research and 
donation of live therapeutic tissue suggest possible influences of donors to tumour 
bank; further empirical research is clearly needed to clarify: the extent to which donors 
trust tumour banks; the impact of open-ended research on the contemporaneous 
decisions of donors; the extent to which potential tumour donors are swayed by fears of 
loss of privacy; the degree to which commercial imperatives influence altruism or gift 
relationships;  the extent to which certain populations (e.g. Aboriginal peoples) are 
motivated by culturally-specific symbolism embedded within tumour samples; and the 
extent to which anxiety surrounding cancer might determine decisions to participate in 
both clinical and tumour banking research.   
 More generally, more thought needs to be given to the impact of the illness 
experience and of the social context on patient decisions to donate. Consent processes 
for tumour banking should take account of the range of potential motives that may 
influence a patient’s decision to donate tissue. This might involve asking patients what 
they know about tumour banking, what they expect from donating their tissue for 
research, whether they have any anxieties about donating their tissue, and if so, what 
they are and how they came to their decision to donate.  This will take time, but 
ultimately it is likely to increase the validity and integrity of the consent process and 
increase trust in and engagement with biomedical research.   
 Given the importance of knowledge about tumour banking to decision-making about 
donation, we argue that issues surrounding tumour banking must enter public discourse 
much like organ donation and clinical research participation are in the public domain.  
This will mean that when patients are faced with decisions of whether or not to 
participate in tumour banking, they will be better equipped with meaning complexes 
and motivational understanding that are necessary to reflect upon and interpret the 
situation and what is being asked of them, and to realize their pragmatic interests.  
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